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ABSTRACT: Aminopyrazoles are a new class of antimalarial compounds identified in
a cellular antiparasitic screen with potent activity against Plasmodium falciparum asexual
and sexual stage parasites. To investigate their unknown mechanism of action and thus
identify their target, we cultured parasites in the presence of a representative member of
the aminopyrazole series, GNF-Pf4492, to select for resistance. Whole genome
sequencing of three resistant lines showed that each had acquired independent
mutations in a P-type cation-transporter ATPase, PfATP4 (PF3D7_1211900), a
protein implicated as the novel Plasmodium spp. target of another, structurally
unrelated, class of antimalarials called the spiroindolones and characterized as an
important sodium transporter of the cell. Similarly to the spiroindolones, GNF-Pf4492
blocks parasite transmission to mosquitoes and disrupts intracellular sodium
homeostasis. Our data demonstrate that PfATP4 plays a critical role in cellular
processes, can be inhibited by two distinct antimalarial pharmacophores, and supports
the recent observations that PfATP4 is a critical antimalarial target.
The need to identify new drugs to combat malaria hasresulted in high-throughput cellular screening campaigns
that have revealed thousands of small molecule inhibitors with
antimalarial activity;1−3 several of which are currently in clinical
trials.4−8 Although a successful method of drug discovery,9,10 a
remaining challenge with cellular screening is in identifying the
targets of lead compounds. Target identification is not essential
for drug development, but nevertheless improves medicinal
chemistry efforts and allows for the design of target-based high-
throughput assays that may yield additional potent inhibitors of
a target of interest.
The current number of chemically validated targets in
Plasmodium spp. remains small11,12 and includes the
cytochrome bc1 complex,
13 inhibition of hemozoin formation,14
phosphatidylinositol-4-OH kinase,6 dihydroorotate dehydro-
genase,15 dihydrofolate reductase,16 and the P-type ATPase,
PfATP4.5 As with other antimalarial targets, P-type ATPases are
important druggable targets in humans with several clinically
relevant inhibitors.17−19 Specifically, PfATP4 belongs to a
subfamily of these proteins (family IID) that function to
extrude monovalent cations (sodium, lithium, and potassium)
from inside the cell. Their presence is limited to lower
eukaryotes (fungi, protozoan, and bryophytes) making them an
attractive drug target.20,21 PfATP4 is the target of the
spiroindolones, a novel antimalarial chemical class discovered
in a cellular screen.5,22,23 In a Phase II clinical trial, this class
was shown to induce faster parasite clearance times than the
current standard of care, artemisinin, and was shown to be
active against artemisinin resistant parasites.24
In this study, we use a chemical genomics approach25 to
identify PfATP4 as the target of another novel class of
inhibitors with antimalarial activity, the aminopyrazoles, which
are structurally distinct from the spiroindolones. We further
show that the phenotypes of spiroindolone- and amino-
pyrazole-treated parasites are similar. We additionally identify
a third chemotype that interacts with PfATP4. Convergence on
this target by multiple chemophores highlights the critical
function of this protein in the parasite. Overall, these data
suggest that the number of druggable targets in P. falciparum
may be smaller than first hypothesized.
■ RESULTS AND DISCUSSION
In Vitro Evolution in the Presence of GNF-Pf4492
Identifies Resistance-Conferring Mutations in P. falcipa-
rum pfatp4. Aminopyrazoles were identified in a high-
throughput cellular screen against P. falciparum asexual blood
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stages.1 A representative compound from the aminopyrazole
series, GNF-Pf4492 (Figure 1a) (N-[4-(4-bromophenyl)-1-
methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]-N′-(2,4-
difluorophenyl)urea, has a mean half maximal (50%) inhibitory
concentration (IC50) of 184.1 nM (95% confidence interval
(CI) 141.3−239.9) against asexual stages of the multidrug
resistant P. falciparum strain, Dd2, and demonstrates no
cytotoxicity against the human heptoma cell line Huh7 (>30
μM). Given that the aminopyrazoles have chemical structures
that are distinct from currently recommended antimalarials and
scaffolds in development, we sought to identify the target of the
aminopyrazoles by evolving resistant parasites and examining
their genomes for changes that contribute to the resistance
phenotype.25
GNF-Pf4492 drug-resistant lines (GNF-Pf4492R) were
selected for in three independent cultures of the multidrug
resistant, clonal P. falciparum Dd2 strain (Dd2EF1) by exposure
to sublethal concentrations of GNF-Pf4492 for 70 days (SI
Figure S1). Each of the resistant clones exhibited mean IC50
values that were significantly greater than the Dd2EF1 parental
line (Figure 1b, SI Table S1) (p < 0.0001) and were 1170 nM
(95% CI 920.5−1483), 811.0 nM (631.0−1040), and 631.0 nM
(458.1−867.0) for GNF-Pf4492R-1, −2 and −3, respectively.
None of the mutants appeared to endure any fitness cost as
they grew at the same rate as the Dd2EF1 parent. GNF-Pf4492
resistance was stable in these lines; that is, when grown without
selective pressure for several months GNF-Pf4492 resistance
was still observed. To identify genetic changes that contribute
to the GNF-Pf4492 resistance phenotype we compared the
genomic sequence of each resistant clone with the sequence of
the Dd2EF1 parent (Table 1).
Single-nucleotide variants (SNVs), as well as copy number
variants (CNVs), contribute to drug resistance in Plasmodium
spp.; therefore, we looked for both types of genetic changes in
our resistant lines.5,26,27 We did not observe any unique CNVs
in the GNF-Pf4492R lines compared to the Dd2EF1 parent
(Figure S2) but did identify SNVs that were unique to the
resistant lines, and therefore arose during selective pressure
with GNF-Pf4492. A total of 15 868, 15 983, and 16 367 SNVs
were confidently identified in GNF-Pf4492R-1, GNF-Pf4492R-
2, and GNF-Pf4492R-3, respectively, compared to the 3D7
reference genome (Table 1). After comparative analysis with
the Dd2EF1 parental line, 74 SNVs were found to be unique: 28
in GNF-Pf4492R-1, 22 in GNF-Pf4492R-2, and 24 in GNF-
Pf4492R-3 (Table 1 and SI Table S2). Of these, six resulted in a
nonsynonymous amino acid substitution in an exon of an open
reading frame (two in each line) (Table 1) and remarkably, all
three lines contained SNVs in PF3D7_1211900 (formerly
Figure 1. Evolution of P. falciparum GNF-Pf4492-resistant parasite
lines. (a) Chemical structure of GNF-Pf4492, a representative
compound from the aminopyrazole series. (b) In vitro drug
sensitivities of the clonal GNF-Pf4492 evolved resistant lines and
the Dd2EF1 parent to GNF-Pf4492 were determined using a SYBR
Green I-based cell proliferation assay. Bars represent mean IC50 from a
minimum of 3 experiments conducted in duplicate. Error bars = 95%
confidence interval. (c) IC50 fold change in transgenic parasite lines
harboring additional wild-type pfatp4 copies (PbEF1α-wt and Pfcam-
wt) or mutated pfatp4 (PbEF1α-I398F/P990R, Pfcam-I398F/P990R
or Pfcam-A211T) under the control of the P. berghei EF1α promoter
or the stronger P. falciparum camodulin promoter compared to Dd2attB
(contains only the isogenic recombination site). Significance values
were determined using one-way ANOVA followed by Dunnett’s
multiple comparison post-test to test for a difference in mean
log(IC50) value between each strain and the parent: ****p < 0.0001;
***p < 0.001; **p < 0.01.
Table 1. Whole Genome Sequencing Identifies SNVs in pfatp4 in All GNF-Pf4492 Resistant Lines
GNF-Pf4492 resistant lines
GNF-Pf4492R-1 GNF-Pf4492R-2 GNF-Pf4492R-3
genome coverage (x) 41 55 55
% covered by 15 or
more reads
80.3 78.1 86.5
SNVs identified
rawa 63 206 62 951 67 348
qualityb 15 868 15 983 16 367
uniquec 28 22 24
intergenic 21 16 20
intronic 4 4 2
synonymous 0 0 0
nonsynonymous 2 2 2
gene (mutation) PF10_0182: conserved protein (K309N),
PFL0590c: PfATP4 (A211T)
PFL0590c: PfATP4 (I203L),
PFL0590c: PfATP4 (P990R)
PF10_0366: ADP/ATP transporter (I301N),
PFL0590c: PfATP4 (A187V)
aAfter alignment to P. falciparum 3D7 reference genome. bQuality filters based on parameters defined in Methods. cCompared to Dd2 parent. No.,
number; SNVs, single-nucleotide polymorphisms; PfATP4, P-type cation ATPase 4.
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PFL0590c), the gene that encodes the P-type cation-trans-
porting ATPase, PfATP4. GNF-Pf4492R-1 and GNF-Pf4492R-
3 each harbored one mutation in pfatp4 (Ala211Thr and
Ala187Val, respectively) while GNF-4492R-2 bore two
mutations (Ile203Leu and Pro990Arg) (Table 1). These two
mutations were the only nonsynonymous substitutions
identified in the entire GNF-Pf4492R-2 genome. Mutations
in all resistant clones were covered by 76 to 93 reads (SI Table
S2), lending high confidence to the base calls, and were further
confirmed by Sanger sequencing.
In addition to the mutations identified in pfatp4, two
additional candidate nonsynonymous coding SNVs were
identified in GNF-Pf4492R-1 and -3. A nonsynonymous
mutation in PF3D7_1018900 (formerly PF10_0182), a gene
encoding a conserved protein of unknown function, was
identified in GNF-Pf4492R-1. Sanger sequencing showed the
expected parental sequence of PF3D7_1018900 in GNF-
Pf4492R-1. It was noted that this SNV occurs in a
homopolymer tract, which causes difficulty for the read
alignment program, therefore causing an isolated false positive
call (SI Figure S3a). In GNF-Pf4492R-3, a third non-
synonymous coding SNV (encoding the mutation Ile301Asn)
was identified in the last amino acid of the polypeptide encoded
by PF3D7_1037300 (formerly PF10_0366). This gene
encodes an ADP/ATP transporter, a protein that enables
ATP and ADP to traverse the inner mitochondrial membrane.28
The human ADP/ATP transporter, which is critical for cellular
respiration, can be chemically inhibited and is the target of the
poisons, bongkrekic acid and atractyloside.29 Interestingly, we
observed a K544N mutation in pfcdpk5 (Pf3D7_1337800) in
all three resistant lines (SI Figure S3b). Although this SNV is
not present in the published Dd2 sequence, it was found in our
Dd2EF1 line. We thus believe that this SNV was not acquired
during GNF-Pf4492 selective pressure.
Because resistance to aminopyrazoles could be conferred by
mutations in pfatp4, one of the noncoding genetic changes, the
mutation in the ADP/ATP transporter, or a yet unidentified
locus, we evaluated a transgenic P. falciparum Dd2 line
containing an attB (Dd2attB) site integrated at the cg6 locus30
expressing one extra gene copy of wild-type pfatp4 under the
control of the P. berghei elongation factor-1 α (EF1α)
promoter5 or the stronger, P. falciparum (camodulin) cam
promoter.5,30 Both stable overexpression transgenic lines
showed a > 1.5× shift in resistance to GNF-Pf4492 compared
to the Dd2attB parent (Figure 1c, SI Table S1). We observed no
change in the IC50 of control compounds and Western blot
analysis with antibodies to PfATP4 confirmed low levels of
overexpression (SI Figure S4a) relative to the Dd2attB parent.
Because resistance in the GNF-Pf4492R-lines was caused by
mutant alleles and not overexpression (SI Figure S4b), we also
evaluated Dd2attB strains expressing mutated copies of pfatp4.
The Pfcam-A211T strain harbors the mutated pfatp4 observed
in the GNF-Pf4492R-1 line. Two additional pre-existing
transgenic lines bearing pfatp4 with two mutations (Ile398Phe
and Pro990Arg) under control of the P. berghei EF1α promoter
or the P. falciparum cam promotor were also evaluated for
cross-resistance.5 We saw a 2-fold increase in resistance in the
PbEF1α-I398F/P990R line. Significantly, we observed a 3.6 and
4.4 fold shift in resistance in the Pfcam-I398F/P990R line and
Pfcam-A211T line respectively, but no shift for other
antimalarials. This increase in resistance in the mutant pfatp4
expressing strains is likely smaller than expected due to
concurrent expression of both wild-type and mutant PfATP4.
Western Blot analysis showed that this does not appear to be
due only to overexpression of the protein (SI Figure S4a).
These data show that mutations in pfatp4 alone confer
resistance to aminopyrazoles.
Aminopyrazole-Resistant Parasite Lines Exhibit
Cross-Resistance with the Spiroindolone Drug Series.
Mutations in pfatp4, whose protein product is implicated in
parasite sodium tolerance,21 also confer resistance to
spiroindolones, a novel class of antimalarial that are currently
in clinical trials.5,23 The pfatp4 mutations associated with
spiroindolone resistance (SI Table S3) were previously
identified using the same methodology, yet with small molecule
inhibitors from the spiroindolone class, either KAE609
(formerly NITD609) or KAE678 (formerly NITD678) (Figure
2a,b).5 The pfatp4 SNVs detected in all aminopyrazole- and
spiroindolone resistant lines are present at or near the predicted
transmembrane (TM) domain of the protein, where cations are
translocated, suggesting a shared structure−function relation-
ship (Figure 2c). All GNF-Pf4492-associated mutations, except
Pro990Arg, occurred in TM helices 1 and 2 (model backbone
colored orange) and corresponded at or near reported KAE678
resistance-conferring mutations: Ala184Ser (yellow), Ile203Met
(yellow; identical location of GNF-Pf4492 mutation), and
Gly223Arg (yellow) (Figure 2c). The Pro990Arg mutation is
located 5 residues before the predicted start of TM helix 7 and,
thus, resides near the TM region. Curiously, as does GNF-
Pf4492R-3, KAE678R-2 also possessed a nonsynonymous
mutation in the ADP/ATP antiporter (Ile119Ser), suggesting
that this may function as a compensatory mutation or possibly
an additional target.28
Because the spiroindolone chemotype is structurally different
from the aminopyrazole class, we did not expect resistance to
both chemical classes would be conferred by mutations in the
same gene. We characterized the extent of cross-resistance
using three closely related members of the spiroindolone series,
KAE609, KAE678, and KAF246 (formerly NITD24621) and
found GNF-Pf4492R-2 and -3 were 3- to 8-fold more resistant,
to the spiroindolones than the Dd2EF1 parent (Figure 2d, SI
Table S1). Surprisingly, GNF-Pf4492R-1, the line most
resistant to the aminopyrazole, showed an increased sensitivity
to the spiroindolones (Figure 2d). This line was 7- to 20-fold
more sensitive to all of the spiroindolone compounds tested
compared to the Dd2EF1 parent. To further investigate this
curious observation, we tested the Pfcam-A211T transgenic line
for cross resistance with KAF246. The Pfcam-A211T showed
some signs of sensitivity while the Pfcam I398F/P990R was >2-
fold more resistant to KAF246 (Figure 2e). Failure to see more
sensitivity introduced with the Pfcam-211T mutation is again
most likely due to the presence of both wild-type and mutant
PfATP4. Similarly, the six independently evolved spiroindo-
lone-resistant lines were also resistant to GNF-Pf4492,
exhibiting 3−15 fold higher IC50 values compared to the
parent (Figure 2f, SI Table S1). No significant change was
observed in IC50 for the controls artemisinin and mefloquine,
demonstrating this effect is specific and not due to a multidrug
efflux mechanism.
To determine if any other publicly available compounds
would have activity against PfATP4, we screened several
inhibitors from the “malaria box,” a set of compounds
previously identified in cellular screens with activity against
blood-stage P. falciparum, for cross-resistance with the GNF-
Pf4492R lines.31 Two of these compounds, MMV666124
(Figure 3a) and MMV020660 (Figure 3b), showed cross-
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resistance with the GNF-Pf4492R lines (Figure 3c). As with the
phenotype observed with the spiroindolones, GNF-Pf4492R-1
did not exhibit cross-resistance with MMV020660 but rather
was more sensitive than the Dd2EF1 parent. Interestingly, the
structure of MMV020660 shows some similarity to GNF-
Pf4492 (Figure 3b).
Aminopyrazoles and Spiroindolones Induce Similar
Phenotypes In Vitro. Given that mutated PfATP4 mediates
aminopyrazole resistance, we hypothesized that the amino-
pyrazoles and spiroindolones share a mechanism of action.
Therefore, we sought to determine whether parasites treated
with inhibitors from either class produced the same phenotype.
Synchronized cultures were treated with 10× IC50 GNF-Pf4492
or KAF246 to observe when the compounds act during the
parasite life cycle. Neither culture treated with inhibitor
advanced past the early trophozoite stage, arresting in the
ring or early trophozoite stages (Figure 4a). Furthermore,
similar to the spiroindolones, GNF-Pf4492 diminished protein
synthesis activity in the trophozoite stage of the Dd2 parent at
10× and 100× IC50 concentrations as measured by
incorporation of radiolabeled methionine and cysteine (SI
Figure S5a). Conversely, protein synthesis progressed unabated
in the KAE609R-1 clone after addition of either 100× KAF246
or GNF-Pf4492 (SI Figure S5b).
Figure 2. Mutations in pfatp4 confer cross-resistance between GNF-
Pf4492 and the spiroindolone class. Chemical structures of
representative spiroindolones (a) KAE609 when X = Cl and
KAF246 when X = F. (b) KAE678 is distinguished by a 7-membered
ring in the tricyclic system. (c) A PfATP4 homology model shows the
location of resistance-conferring mutations specific to the amino-
pyrazole GNF-Pf4492 (blue) and the spiroindolones KAE609 (red)
and KAE678 (yellow). Nearly all resistance-conferring mutations
Figure 2. continued
occur within or near PfATP4 transmembrane domains (approximated
by dashed lines). Transmembranes 1 and 2 are in orange. (d) The
three GNF-Pf4492-resistant linesGNF-Pf4492R-1, GNF-Pf4492R-2,
and GNF-Pf4492R-3were tested for cross-resistance against a panel
of spiroindolones (KAE609, KAE678, and KAF246). The IC50 shift is
relative to the GNF-Pf4492-sensitive Dd2EF1. Artemisinin (ART) and
mefloquine (MFQ) were used as controls. (e) IC50 log2 fold change in
transgenic lines harboring either wild-type pfatp4 (PbEF1α-wt and
Pfcam-wt) or mutated pfatp4 (PbEF1α-I398F/P990R, Pfcam-I398F/
P990R or Pfcam-A211T). (f) Resistant lines (three each) were
independently evolved to spiroindolone analogs KAE609 and
KAE678. These lines were tested for cross-resistance against GNF-
Pf4492. ART and MFQ were used as controls. Significance values were
determined using one-way ANOVA followed by Dunnett’s multiple
comparison post-test to test for a difference in mean log(IC50) value
between each strain and the parent: ****p < 0.0001; *p < 0.01.
Figure 3. GNF-Pf4492-R lines show cross-resistance to the malaria
box inhibitors MMV666124 and MMV020660. Chemical structure of
compounds known to have blood-stage antimalarial activity (a)
MMV666124 and (b) MMV020660. (c) Log2 fold change in IC50 for
GNF-Pf4492R lines compared to the Dd2EF1 parent. Bars represent
mean log2(IC50 fold change) from a minimum of 3 experiments
conducted in duplicate. Error bars = SEM; Significance values were
determined using one-way ANOVA followed by Dunnett’s multiple
comparison post-test to test for a difference in mean log2(IC50)
between each strain and the Dd2EF1 parent; *p < 0.05, **p < 0.01.
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While phenocopy was observed for drug-treated parasites in
the asexual blood stages, we continued characterization of these
inhibitors in the liver and sexual blood stages. Addition of
GNF-Pf4492 or KAF246 to P. yoelii sporozoite-invaded HepG2
cells4 resulted in no detectable reduction in parasite growth at
10 μM, the highest concentration tested (SI Table S4). Van
Pelt Koops et al. demonstrated that the spiroindolones are
capable of blocking transmission to mosquitoes.32 Therefore,
we used a standard membrane-feeding assay to assess the
effectiveness of GNF-Pf4492 in preventing P. falciparum oocyst
development in the mosquito33 GNF-Pf4492 or KAF246
inhibitors were added at three different concentrations directly
to a parasite blood meal. This resulted in a dose-dependent
decrease in the number of oocysts formed in the mosquito
midguts 8 days after feeding (Figure 4b). The strongest effect
was observed for the 100× IC50 concentration for both GNF-
Pf4492 and KAF246 (mean oocyst count of 0.63 and 1.33,
respectively). At these concentrations, 30 nM KAF246 and 15
μM GNF-Pf4492, a respective reduction of 60% and 38% of the
control was observed. Additionally, as compound concentration
was increased, the percentage of mosquitoes infected also
decreased (Figure 4c).
GNF-Pf4492 Causes an Increase in Intracellular
Sodium Concentration in P. falciparum. Recent studies
show that PfATP4 functions to transport sodium against a
concentration gradient, out of the cell, maintaining a low
intracellular sodium concentration in the presence of the high
sodium environment of the infected red blood cell.21,34,35
Therefore, we sought to determine whether both compounds
would affect sodium concentration within the parasite
cytoplasm. When 100× IC50 GNF-Pf4492 (Figure 5a) or
KAF246 (Figure 5b) was added, a rapid, steady, and
comparable increase in intracellular sodium concentration
([Na+]i) was observed over a 30 min period and this response
was demonstrated to be dose-dependent in the presence of
GNF-Pf4492. For GNF-Pf4492R-1 and -2, when treated with
compound these lines maintained the same [Na+]i over the
observation period (Figure 5a, SI Figure S6a). While a dose-
dependent response was observed for GNF-Pf4492R-3, [Na+]i
concentrations did not reach those of the Dd2EF1 after 30 min
of observation after addition of the inhibitor (SI Figure S6a). In
the presence of KAF246, in the GNF-Pf4492R-1 mutant, which
is hyper-sensitive to KAF246, a similar pattern of increase in
[Na+]i was observed as the parent (Figure 5b). For the highest
concentration of KAF246 used (100× IC50), increases in [Na
+]i
were similar for the GNF-Pf4492R-2 and -3 mutants, although
the final [Na+]i remained suppressed below that observed in the
parental line (SI Figure S6b). The resting [Na+]i concentrations
for GNF-Pf4492R-1 and -2 were consistently higher than that
of the parent (SI Table S5).
Conclusions. New phenotypic screening efforts have
unveiled novel antimalarial chemotypes with correspondingly
novel mechanisms of action.4,5,36 Inherently, the identification
of targets of compound hits originating from cellular screens
requires deconvolution. Target identification for one of these
compounds, the aminopyrazole GNF-Pf4492,1 reveals it
phenocopies the spiroindolone series, a chemical class shown
in Phase II clinical trials to induce faster parasite clearance
times than artemisinin.5,24 We demonstrate that cross-
resistance between aminopyrazole and spiroindolone series is
mediated by mutations in pfatp4, a gene encoding a P-type
ATPase that functions as a Na+/H+ pump at the parasite plasma
membrane.21 A third chemotype associated with resistance-
conferring mutations in pfatp4, dihydroisoquinolones, (http://
www.mmv.org/research-development/rd-portfolio),37 has pro-
gressed to preclinical evaluation as well. The convergence on
the same target by inhibitors of unrelated compound classes is
not uncommon for antimalarials and does not preclude their
Figure 4. Phenotypic characterizations of parasites treated with
aminopyrazoles or spiroindolones. (a) The lifecycle stage of action of
GNF-Pf4492 and KAF246 were determined by addition of either 10×
IC50 of GNF-Pf4492 or KAF246 and observation over a 60 h period.
(b, c) Standard membrane feeding with P. falciparum to determine
inhibitor action on transmission. Ten to forty mosquitoes per feeding
were dissected. (b) Geometric mean number of oocysts counted per
feeding. Bars represent median. Squares, GNF-Pf4492 treated;
triangles, KAF246 treated. (c) The percent of mosquitoes that had
one or more oocysts per the total number of mosquitoes dissected.
Figure 5. Structure−function relationship between PfATP4 mutations
and compound treatment. Effects of (a) aminopyrazole and (b)
spiroindolone inhibitors on intracellular sodium concentration [Na+]i
in the Dd2EF1 and GNF-Pf4492R-1 strains. [Na+]i traces for extracted
trophozoite-stage parasites treated with saline or inhibitor immediately
prior to fluorescence acquisition. Inhibitors were added at 1 × , 3×,
10×, or 100× the IC50 for the Dd2
EF1 parent. Traces are representative
of those obtained from a minimum of four independent experiments
performed in duplicate. Calibration curves were generated for each
strain and each experimental replicate to determine [Na+]i.
ACS Chemical Biology Articles
dx.doi.org/10.1021/cb500616x | ACS Chem. Biol. 2015, 10, 413−420417
importance as good drug targets. In the case of cytochrome bc1,
the validated mitochondrial protein target of atovaquone,38,39
although several other inhibitors target it,27,40,41 atovaquone is
used clinically with wide success for prophylaxis.42 Identi-
fication of mutations in pfatp4 that mediate resistance to
multiple compound classes suggests its importance as a drug
target, although the novel mechanism of action is unclear.
Insight into the mechanism of action of PfATP4 targeting
inhibitors is gleaned from the location of amino acid changes
conferring resistance. The pfatp4 mutations we identify localize
to the transmembrane domain suggesting inhibitors bind in the
clefts within transmembrane helices. Clinically relevant p-type
ATPase inhibitors bind to transmembrane helices leading to
poor cation recognition or unfavorable enzymatic conforma-
tions.18 We speculate that PfATP4 targeting compounds
disrupt sodium export in an analogous manner to other P-
type ATPase targeting drugs and that there is most likely a
small structural element common to the two classes that
accounts for both compound classes binding to the same
druggable pocket. Resistance conferring PfATP4 mutations
disrupt binding of the inhibitor to this pocket and such
mutations could be expected to alter the function of the
enzyme, which may be reflected in the slightly elevated resting
sodium concentrations observed in two of the resistant lines. In
the case of the mutations observed in the GNF-Pf4492R-1 line,
a single mutation renders the strain resistant to the amino-
pyrazole yet sensitive to the spiroindolone (as phenomena
observed with other P-type ATPase inhibitors43), suggesting
the binding sites of each inhibitor are overlapping, yet unique.
Although our data suggests PfATP4 is the target of the
spiroindolone and aminopyrazole compound series, alternative
explanations exist, including a different biological function for
PfATP4 (i.e., as a nonselective drug transporter), mutation of
PfATP4 as a secondary, compensatory mutation in response to
an as-of-yet unidentified target and last, PfATP4 function is
sodium dependent, thus acting downstream of the true target.
We evaluated the activity of other antimalarials (mefloquine
and artemisinin) against aminopyrazole resistant lines and
noted a low-incidence of cross-resistance, a finding inconsistent
with the function of PfATP4 as a nonselective drug transporter.
Furthermore, if PfATP4 is only involved in inhibitor efflux, we
also might expect different chemical phenotypes, which we do
not observeaminopyrazoles and spiroindolones behave
similarly throughout the lifecycle. The expression of these
mutants alone was sufficient to confer aminopyrazole
resistance, suggesting these are not compensatory mutations
nor that PfATP4 is downstream of the true target and that
PfATP4 plays a direct role in the mechanism of action of
aminopyrazole antimalarials.
Other reports have used in silico modeling to predict that the
pyrazole series might act by disrupting the protein−protein
interaction between the P. falciparum myosin motor compo-
nent myosin A and the myosin tail interacting protein (MTIP),
a complex necessary for parasite reinvasion of red blood cells.44
Despite showing P. falciparum blood-stage activity, docking
studies were done in silico thus not directly validating the
interaction between MTIP and aminopyrazoles. In addition, we
show aminopyrazoles are active throughout the asexual life
cycle and not just during cell invasion or gliding motility, which
requires the MTIP-myosin A interaction.45,46
One open question is whether PfATP4 is the target of or a
gene involved in resistance to both the aminopyrazoles and the
spiroindolones. While the underlying mechanism by which
PfATP4 inhibitors affect sodium levels in the cell remains to be
elucidated, that mutations in PfATP4 are responsible for
resistance to two (and possibly three) structurally unrelated
compounds has important implications for future drug
discovery efforts. It is difficult to imagine that convergence
on PfATP4 is coincidental, given that both these drug series
were identified by large chemical library screens and their
relationship to PfATP4 identified by unbiased genomic
sequencing of independently generated resistant lines. Because
these screens produced antimalarial compounds acting through
a variety of targets, we do not think the libraries are biased for
PfATP4 inhibitors.1−3 Therefore, there must be other reasons
for target convergence. One possible explanation is that
PfATP4 may represent a particularly strong drug target,
perhaps owing to its molecular structure of physiologic
importance. Although current Phase II clinical trials of the
spiroindolones are very positive, they may have high production
costs due to their chiral centers.22 Investigation into other
chemical classes, such as the aminopyrazoles, that interact with
PfATP4 may represent an important alternative for combina-
tion therapies. Another possible reason for target convergence,
may be that the number of suitable drug targets in Plasmodium
is smaller than anticipated. Either way the role of PfATP4 as an
important, novel antimalarial target warrants further study.
■ METHODS
See detailed version in SI Materials and Methods.
Evolution of Compound-Resistant Lines, Sensitivity Testing
and Construction of Transgenic Parasite Lines. The P. falciparum
multidrug resistant strain Dd2EF1 was cultured in triplicate in the
presence of increasing concentrations of GNF-Pf4492 to generate
resistant mutants as previously described.5 After ∼70 days of selection,
parasites were cloned in 96-well plates by limiting dilution.47 The half
maximal (50%) inhibitory concentration (IC50) of each compound
against blood-stage P. falciparum Dd2EF1 was determined in dose−
response format using a SYBR Green I-based cell proliferation assay as
previously described.1 Liver-stage IC50 was determined as previously
described.4 Transgenic parasite lines were created as previously
described.5 Briefly, P. falciparum Dd2 containing the attB recombina-
tion site was transfected with the wild-type or mutant pfatp4 transgene
under the control of either the P. berghei elongation factor-1α 5′ UTR
(PbEF1α) or the stronger P. falciparum calmodulin 5′ UTR (Pbcam).
Whole Genome Sequencing. DNA libraries of each sample were
prepared using the Illumina TruSeq version 3 protocol (Illumina, Inc.,
San Diego, CA) of fragmentation, end-repair, and adapter ligation.
Libraries were clustered and run on an Illumina HiSeq 2000 according
to manufacturer’s instructions. Fifty base pair, single-end reads were
analyzed and aligned to the P. falciparum 3D7 reference genome
(PlasmoDB v. 9.0) as previously described.48 Sequence alignments
were put through a custom quality control procedure.48 SNVs were
initially detected using the Genome Analysis Toolkit (GATK v1.6)
and then filtered using the Plasmodium Type Uncovering Software, an
integrated pipeline developed in our lab that can also call CNVs.48 All
nonsynonymous SNVs were confirmed using Sanger sequencing.
Phenotypic Assays for Parasite Characterization. An E. coli
expression vector was constructed to express pure recombinant
protein and mice were immunized to generate an antibody to the N-
domain of PFATP4. Western blots were performed with 10 or 50 μg
protein lysate and hybridized with the PfATP4 N-domain antibody to
quantify protein levels in the cells. A previously generated homology
model of PfATP45 was used to map the resistance-conferring
mutations identified in the GNF-Pf4492-resistant lines. The PyMOL
Molecular Graphics System (version 1.2r2, Schrödinger, LLC,
Portland, OR) was used to render the model and prepare the figure.
Compound stage of action and protein synthesis inhibition studies
were conducted as previously described.5 The standard membrane
feeding assay was performed as previously described.49 P. falciparum
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NF54 was maintained in vitro in continuous cultivation with daily
media changes and without the addition of fresh red blood cells to
stimulate gametocytogenesis. Day 13, 15, and 17 gametocyte cultures
that exhibited exflagellation were combined to form a mosquito
bloodmeal supplemented with GNF-Pf4492 or KAF246 at 1×, 10×, or
100× the mean IC50 value for blood-stage parasites. Intracellular
sodium concentration ([Na+]i) within the parasite was determined as
previously described.21 50 μL of dye-loaded cells (2 × 109 cells/mL)
were seeded into a black 384-well assay plate fluorescence was
measured on an EnVision Multilabel reader (PerkinElmer, Waltham,
MA).
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